Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pan-tumor × Oxaliplatin × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 71 Stomach Neoplasms 58 Rectal Neoplasms 36 Colonic Neoplasms 29 Pancreatic Neoplasms 25 Esophageal Neoplasms 23 Neoplasms 19 Lymphoma, Large B-Cell, Diffuse 19 Adenocarcinoma 19 Neoplasm Metastasis 14 Cholangiocarcinoma 14 Carcinoma, Non-Small-Cell Lung 12 Adenocarcinoma Of Esophagus 12 Ovarian Neoplasms 10 Biliary Tract Neoplasms 10 Gastrointestinal Neoplasms 8 Gallbladder Neoplasms 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Locally Advanced Rectal Cancer 5 Recurrence 4 Lymphoma 4 Esophageal Squamous Cell Carcinoma 4 Endometrial Neoplasms 4 Carcinoma 4 Bile Duct Neoplasms 4 Advanced Solid Tumors 4 Triple Negative Breast Neoplasms 3 Peritoneal Neoplasms 3 Lymphoma, Non-Hodgkin 3 Lung Neoplasms 3

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡